# US 2026/0007740 A1 · Vaccine composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0007740 A1
- Document ID: US20260007740A1
- Status: Published application
- Kind: A1
- Application number: 19/323,644
- Filed: 2025-09-09
- Published: 2026-01-08
- Earliest claimed: 2018-05-04
- Assignees: SpyBiotech Limited
- Applicants: SpyBiotech Limited
- Inventors: Sumi BISWAS; Jing JIN; Rebecca Alice DABBS; Genevieve Marie Catherine LABBÉ
- Web page: https://patentgrep.com/patent/US20260007740A1

## CPC

- A61K 39/245: Herpetoviridae, e.g. herpes simplex virus
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- C07K 14/005: from viruses
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/6068: {Other bacterial proteins, e.g. OMP}
- A61K 2039/6075: {Viral proteins}
- A61K 2039/627: {characterised by the linker}
- C07K 2319/735: containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
- C12N 2710/16123: Virus like particles [VLP]
- C12N 2710/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18523: Virus like particles [VLP]
- C12N 2760/18534: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to vaccine compositions, most notably vaccine compositions wherein the antigenic component is large, for example over 50 kDa, or multimeric, i.e. comprised of subunits. Such antigenic components are of particular interest, because they may represent antigenic components from pathogens that currently it is not possible to vaccinate against. The invention relates to a composition comprising a particle displaying an antigenic component, wherein said composition comprises an antigenic component comprising a first peptide tag, and a moiety comprising a second peptide tag, wherein the antigenic component and the moiety are linked via an isopeptide bond between said first and second peptide tags, and wherein the antigenic component is over 50 kDa, or alternatively is multimeric.

## Claims

### Claim 1

A composition comprising:
an antigenic component comprising a first peptide tag; and
a moiety comprising a second peptide tag,
wherein the antigenic component and the moiety are linked via an isopeptide bond between the first peptide tag and the second peptide tag, and wherein a molecular weight of the antigenic component is greater than 50 kDa.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the molecular weight of the antigenic component is greater than 60 kDa, 70 kDa, 80 kDa, 90 kDa, 100 kDa, 110 kDa, 120 kDa, 130 kDa, 140 kDa, 150 kDa, 160 kDa, 170 kDa, 180 kDa, 190 kDa, 200 kDa, 300 kDa, or 400 kDa.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the antigenic component is a monomer or multimer.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the multimer is a dimer, trimer, tetramer, pentamer, hexamer, septamer, octamer, nonamer or decamer.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the moiety comprises a virus, a bacterium, a multimerisation scaffold for vaccination, a protein component which multimerises to form a virus-like particle (VLP), a viral structural protein, a multimerisation domain which forms nanoparticles, a synthetic nanoparticle, or a synthetic VLP.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the moiety comprises a Hepatitis B Surface Antigen (HBsAg).

### Claim 7 (depends on 1)

The composition of claim 1, wherein the first peptide tag and the second peptide tag are selected from:
a SpyTag and SpyCatcher pair;
a SnoopTag or SnoopTagJr and SnoopCatcher pair;
a RrgATag, RrgATag2 or DogTag and RrgACatcher pair,
an IsopepTag Pilin-C pair;
an IsopepTag-N and Pilin-N pair;
a PsCsTag and PsCsCatcher pair; or
a SnoopTagJr and DogTag pair mediated by SnoopLigase.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the first peptide tag is a SpyTag.

### Claim 9 (depends on 8)

The composition of claim 8, wherein SpyTag has the amino acid sequence set out in SEQ ID NO:30.

### Claim 10 (depends on 8)

The composition of claim 8, wherein the SpyTag is attached via a linker.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the linker has the amino acid sequence set out in SEQ ID NO:29.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the moiety comprises a Hepatitis B Surface Antigen (HBsAg) and the second peptide tag is a SpyCatcher.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the SpyCatcher has the amino acid sequence set out in SEQ ID NO:38.

### Claim 14 (depends on 12)

The composition of claim 12, wherein the SpyCatcher is attached to the HBsAg via a linker.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the linker has the amino acid sequence set out in SEQ ID NO:39.

### Claim 16 (depends on 1)

An immunogenic composition or vaccine composition comprising the composition of claim 1.

### Claim 17 (depends on 1)

A method of producing the composition of claim 1, the method comprising:
introducing a first nucleic acid encoding a first genetic fusion of a first protein to the first peptide tag into a first host cell;
incubating the first host cell under conditions for expressing the first genetic fusion;
introducing a second nucleic acid encoding a second genetic fusion of a second protein to the second peptide tag into a second host cell;
incubating the second host cell under conditions for expressing the second genetic fusion; and
incubating the first genetic fusion and the second genetic fusion under conditions for formation of an isopeptide bond between the first peptide tag and the second peptide tag to produce the composition.

### Claim 18 (depends on 17)

The method of claim 17, wherein the first protein comprises the antigenic component and the second protein comprises the moiety.

### Claim 19 (depends on 1)

A kit comprising a first immunogenic composition, wherein the first immunogenic composition comprises the composition of claim 1.

### Claim 20 (depends on 1)

A kit comprising an immunogenic composition and a booster composition, wherein the immunogenic composition and/or the booster composition comprises the composition of claim 1.

### Claim 21 (depends on 1)

A method of treating a subject, the method comprising administering to the subject the composition of claim 1.

### Claim 22 (depends on 21)

The method of claim 21, wherein the method treats an infection or infectious agent in the subject.
